Tag : OFATUMUMAB

Ofatumumab is a fully human monoclonal antibody (mAb) against CD20. Monthly subcutaneous injections of ofatumumab 20mg have previously been approved for the treatment of relapsing multiple sclerosis (RMS) in adult patients. Previously in the phase 3 ASCLEPIOS I/II trials, ofatumumab led to a greater reduction of the clinical and magnetic resonance imaging (MRI) disease activity in people with RMS (pwRMS) up to 30 months compared with teriflunomide. Additionally, results from the open-label extension (OLE) study, ALITHIOS, substantiated the sustained efficacy of ofatumumab in pwRMS for up to 5 years. In the captioned analysis, the longer-term safety and efficacy of ofatumumab treatment for up to 6 years in pwRMS were evaluated to further elucidate the benefit-risk profile of ofatumumab in pwRMS.